Elan narrowed losses in the first quarter of 2006 due to strong revenue growth and restated its confidence that Tysabri would return to the market.
The pharmaceutical group said net first quarter loss amounted to $33.3 million, a decrease of 71 per cent on the $115.6 million reported in the same quarter of 2005.
Elan put the improved performance down to strong growth in product revenue which grew by 31 per cent to $134.3 million.
On the key issue of the future of Tysabri, Elan said it expects a final ruling from the US drug watchdog on or before June 28th.
Shane Cooke, Elan's chief financial officer, said: "We remain committed to making Tysabri available for patients in the United States and Europe and are confident that, with the financial leverage we have created over the last year, revenues from Tysabri will accelerate our return to profitability."